SATB1 and breast cancer: SATB1-expression has been demonstrated to confer a more aggressive tumour phenotype and a shorter patient survival in several cancer forms, e.g. breast cancer [3], prostate cancer [6], laryngeal squamous cell carcinoma [7], nasopharyngeal cancer [8], hepatocellular carcinoma [9], rectal cancer [10], cutaneous malignant melanoma [11], epithelial ovarian cancer [12], glioma [13] and gastric cancer [14].